The US Food and Drug Administration has expanded the approved indications for Boston Scientific’s SYNERGY BP everolimus-eluting platinum chromium coronary stent to include patients at high risk for bleeding, the company announced on 11 August.
This
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?